Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Depreciation & Amortization (CF): 2015-2024

Historic Depreciation & Amortization (CF) for Sunshine Biopharma (SBFM) over the last 10 years, with Dec 2024 value amounting to $223,527.

  • Sunshine Biopharma's Depreciation & Amortization (CF) rose 48.78% to $96,163 in Q3 2025 from the same period last year, while for Sep 2025 it was $298,888, marking a year-over-year increase of 49.09%. This contributed to the annual value of $223,527 for FY2024, which is 49.87% up from last year.
  • Sunshine Biopharma's Depreciation & Amortization (CF) amounted to $223,527 in FY2024, which was up 49.87% from $149,147 recorded in FY2023.
  • Sunshine Biopharma's 5-year Depreciation & Amortization (CF) high stood at $223,527 for FY2024, and its period low was $12,741 during FY2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $149,147 (2023), whereas its average is $132,612.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first declined by 9.42% in 2021, then soared by 492.72% in 2023.
  • Sunshine Biopharma's Depreciation & Amortization (CF) (Yearly) stood at $14,066 in 2020, then fell by 9.42% to $12,741 in 2021, then surged by 97.50% to $25,163 in 2022, then soared by 492.72% to $149,147 in 2023, then skyrocketed by 49.87% to $223,527 in 2024.